Substantial Reported Revenue Increase Driven by M&A
Q1 GAAP revenue was $106.2M, up 333% year-over-year on a reported basis, reflecting recently closed acquisitions (Deep Roots, Proper, Wholesome, Eaze, Schwazze, Hawthorne and the PharmaCann MSA).
Pro Forma Scale and Market Ranking
Pro forma revenue (including recent transactions as if completed Jan 1, 2026) was $210.2M, up 5% year-over-year, positioning the company as the fourth largest cannabis company by revenue.
Strong Profitability Metrics and Margin Expansion
Adjusted EBITDA was ~$32.7M (30.8% of sales), an improvement of approximately $26.1M and 390 basis points year-over-year. Excluding non-cash inventory fair-value step-ups, gross margin was 56.3%, up 280 basis points versus prior-year quarter.
Pro Forma Adjusted EBITDA Growth
On a pro forma basis, adjusted EBITDA increased 29.8% to $42.2M and represented 20.1% of sales versus $32.5M or 16.2% of sales in the prior-year quarter.
Significant Cash and Liquid Balance Sheet
Ended the quarter with $137.8M of cash and an additional $1M of marketable securities; total current assets (ex. tax receivables/assets for sale) were $240M vs current liabilities of $82M (ex. uncertain tax liabilities).
Expanded National Footprint and Retail Scale
Now operating in 10 states with over 160 dispensaries; announced that recent deals added over $100M of quarterly revenue to the top line and the company holds leading positions in Colorado, Utah and Nevada and meaningful share in Minnesota and Missouri.
Strategic M&A and Partnerships Targeting Key Markets
Announced FLUENT (Florida) and Glass House (California) transactions: Glass House pairs Vireo retail/delivery (Eaze) with low-cost production in California; FLUENT expands Florida footprint to create a top-three platform with limited store overlap and ~70 combined stores between the two companies.